ID

13806

Descrizione

Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia (AML) or High Grade Myelodysplastic Syndrome (MDS); ODM derived from: https://clinicaltrials.gov/show/NCT01311258

collegamento

https://clinicaltrials.gov/show/NCT01311258

Keywords

versioni (1)
  1. 07/03/16 07/03/16 -
Titolare del copyright

CC BY-NC 3.0

Caricato su

7 marzo 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Acute Myeloid Leukemia NCT01311258

Inglese

Eligibility Acute Myeloid Leukemia NCT01311258

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
are being evaluated for the diagnosis and/or treatment of acute myelogenous leukemia or high grade mds (defined as greater than 10 percent blasts on examination of the bone marrow aspirate).
Descrizione

AML MDS

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2]
C3463824
have not undergone prior cytotoxic therapy for aml or high grade mds in the past 3 months other than hydroxyurea or revlamid.
Descrizione

prior therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0677881
UMLS CUI [2]
C0591617
have not previously received an allogeneic peripheral blood or bone marrow stem cell transplant for their disease.
Descrizione

allogeneic peripheral blood or bone marrow stem cell transplant

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1518999
UMLS CUI [2]
C0842093
are able to sign an informed consent. informed consent must be signed at the time of enrollment and prior to the collection of any specimens and/or clinical data (other than phi needed to screen and identify patients, which will be promptly discarded in a secure fashion if patient is not enrolled on study)
Descrizione

informed consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
are at least 18 years of age.
Descrizione

age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
do not have any serious medical or psychiatric illness, other than that treated by this study which would limit the ability of the patient to receive therapy or give informed consent.
Descrizione

comorbidity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0009488
have been informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.
Descrizione

informed consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects who are less than 18 years of age.
Descrizione

age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
subjects with limited decision making capacity.
Descrizione

subjects with limited decision making capacity.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
subjects who have received prior cytotoxic therapy, other than hydroxyurea or revlamid, for their disease within the past three months.
Descrizione

prior cytotoxic therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0677881
UMLS CUI [2]
C0591617
patients with a diagnosis of cml in blast crisis, acute promyelocytic leukemia, or bi-lineage leukemia.
Descrizione

cml in blast crisis, apl

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0023473
UMLS CUI [1,2]
C0005699
UMLS CUI [2]
C0023487
UMLS CUI [3]
C4023020
subjects who have previously undergone an allogeneic peripheral blood stem cell transplant.
Descrizione

allogenic blood stem cell transplant

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0242602
UMLS CUI [1,2]
C1515895
have an active malignancy other than aml or mds at the time of evaluation or a prior history of treatment for a malignancy other than aml or mds within the past 2 years.
Descrizione

other malignancy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0205394
UMLS CUI [2,1]
C1514463
UMLS CUI [2,2]
C0003392
Ritorna all'inizio della pagina

Similar models

Eligibility Acute Myeloid Leukemia NCT01311258

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
AML MDS
Item
are being evaluated for the diagnosis and/or treatment of acute myelogenous leukemia or high grade mds (defined as greater than 10 percent blasts on examination of the bone marrow aspirate).
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2])
prior therapy
Item
have not undergone prior cytotoxic therapy for aml or high grade mds in the past 3 months other than hydroxyurea or revlamid.
boolean
C1514463 (UMLS CUI [1,1])
C0677881 (UMLS CUI [1,2])
C0591617 (UMLS CUI [2])
allogeneic peripheral blood or bone marrow stem cell transplant
Item
have not previously received an allogeneic peripheral blood or bone marrow stem cell transplant for their disease.
boolean
C1518999 (UMLS CUI [1])
C0842093 (UMLS CUI [2])
informed consent
Item
are able to sign an informed consent. informed consent must be signed at the time of enrollment and prior to the collection of any specimens and/or clinical data (other than phi needed to screen and identify patients, which will be promptly discarded in a secure fashion if patient is not enrolled on study)
boolean
C0021430 (UMLS CUI [1])
age
Item
are at least 18 years of age.
boolean
C0001779 (UMLS CUI [1])
comorbidity
Item
do not have any serious medical or psychiatric illness, other than that treated by this study which would limit the ability of the patient to receive therapy or give informed consent.
boolean
C0009488 (UMLS CUI [1])
informed consent
Item
have been informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
age
Item
subjects who are less than 18 years of age.
boolean
C0001779 (UMLS CUI [1])
subjects with limited decision making capacity.
Item
subjects with limited decision making capacity.
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
prior cytotoxic therapy
Item
subjects who have received prior cytotoxic therapy, other than hydroxyurea or revlamid, for their disease within the past three months.
boolean
C1514463 (UMLS CUI [1,1])
C0677881 (UMLS CUI [1,2])
C0591617 (UMLS CUI [2])
cml in blast crisis, apl
Item
patients with a diagnosis of cml in blast crisis, acute promyelocytic leukemia, or bi-lineage leukemia.
boolean
C0023473 (UMLS CUI [1,1])
C0005699 (UMLS CUI [1,2])
C0023487 (UMLS CUI [2])
C4023020 (UMLS CUI [3])
allogenic blood stem cell transplant
Item
subjects who have previously undergone an allogeneic peripheral blood stem cell transplant.
boolean
C0242602 (UMLS CUI [1,1])
C1515895 (UMLS CUI [1,2])
other malignancy
Item
have an active malignancy other than aml or mds at the time of evaluation or a prior history of treatment for a malignancy other than aml or mds within the past 2 years.
boolean
C0006826 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C1514463 (UMLS CUI [2,1])
C0003392 (UMLS CUI [2,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial